drugset
drugset / Trial / NCT04823702

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

NCT04823702 ↗

Phase 1 Completed 36 enrolled NGM Biopharmaceuticals, Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function

Timeline

Start
2021-04-01
Primary completion
2021-11-19
Completion
2021-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldafermin Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.